Numerous studies have suggested that both EGCG and erlotinib significantly inhibit p-EGFR, p-ERK and p-AKT in SCCHN and that this is associated with a marked increase in apoptosis [38,40,41]. Here, EGFR is linked to head and neck squamous cell carcinoma.